Eli Lilly promotes Edgardo Hernandez to head its manufacturing operations as 19-year vet O'Neill hits the exit
Edgardo Hernandez is being promoted to fill the shoes of Myles O’Neill, who’s leaving the top manufacturing post at Eli Lilly after a 19-year run at the company.
“Myles added to the strong foundation of Lilly manufacturing through his leadership of numerous productivity initiatives, the initiation of our new site in North Carolina and, most recently, by successfully navigating the challenges of manufacturing during the global pandemic,” noted CEO Dave Ricks on the changing of the guard.
Now Hernandez will be a direct report to Ricks as the pharma giant follows up on plans to expand the portfolio.
One of his biggest tasks will be assuming responsibility for the supply of Eli Lilly’s antibody cocktail for Covid-19, one of the few therapies to make it across the EUA line so far at the FDA. Just days ago the US government inked a $210 million deal to buy a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together. And there’s an option for 1.1 million more doses through November 25.
The government had already contracted to buy 1,450,000 doses of bamlanivimab alone, with more than 1 million doses delivered and 450,000 additional doses due by March 31.
Hernandez earned his bachelor’s degree in chemical engineering from the University of Puerto Rico – Mayaguez and his master’s in chemical engineering from North Carolina State University. Before moving to Lilly 16 years ago, he did a stint at Pfizer.
His career at Lilly has included roles in engineering services and manufacturing strategy, as well as manufacturing site-head roles in Puerto Rico, France, and the United States. “He currently oversees Lilly’s parenteral and device manufacturing network, as well as the company’s global supply chain activities. Hernandez will assume his new role on May 2, 2021.”